Hepatitis C virus therapy: No one will be left behind.

Affiliation

Hepato-Gastroenterology Department, Hospital Saint Joseph, 26 Bd de Louvain, 13008 Marseilles, France. Electronic address: [Email]

Abstract

The advent of oral direct-acting antiviral agents (DAAs) has dramatically improved the hepatitis C treatment landscape in the last 4 years, providing cure rates over 95% with shorter duration of treatment and a very good safety profile. This gave access to treatment to almost all Hepatitis C virus (HCV)-infected patients. The launch of two pangenotypic fixed-dose combinations (FDCs) in 2017 was a step forward in hepatitis C treatment, by slightly increasing efficacy and more importantly allowing the treatment of patients without HCV genotyping, and in some cases without fibrosis assessment. New triple regimens have solved the issue of retreatment of the few patients who present failure to DAAs therapy. In the present review we describe the current HCV landscape that allows almost all HCV-infected patients to be cured.

Keywords

Daclatasvir,Glecaprevir,Grazoprevir,Pibrentasvir,Sofosbuvir,Velpatasvir,

OUR Recent Articles